BIO08404-T1

A B cell depleting agent for the treatment of Atherosclerosis or post Myocardial Infarction

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated diseases might also benefit from a reduction of cardiovascular risk through limitation of atherosclerotic lesion development or inflammation. CD20-antibody-mediated depletion of mature B lymphocytes impeded monocyte mobilization, limited myocardial injury and improved heart function after acute MI in mice. Results in various animal models; Availability and safety of humanized monoclonal anti-CD20 antibodies in humans. (Zouggari Y. et al., Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al., J Exp Med. 2010 Aug 2;207(8):1579-87.)


Keywords : Atherosclerosis, B cell depleting agent, B cell, Anti-CD20 mAb, CD20, Antibody
Patent Application number : EP09305013.6
Patent Application date : 2009-01-07
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : Yes
Inventors : Alain TEDGUI
Ziad MALLAT
Thomas TEDDER
Hafid AIT-OUFELLA
Publications :
  • Zouggari Y. et al., Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al., J Exp Med. 2010 Aug 2;207(8):1579-87.

Related offers


The 10 Last viewed

You haven't seen any form yet.